A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Dec 2017 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 28 Dec 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 14 Apr 2016 Status changed from not yet recruiting to recruiting.